BDTX Black Diamond Therapeutics, Inc.
$1.43
Black Diamond Therapeutics, Inc. (BDTX) Earnings News
Earnings press releases, previews and reviews for Black Diamond Therapeutics, Inc. (BDTX), newest first.
Tuesday
November 10, 2026
6:30 AM ET
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
Monday
November 9, 2026
4:01 PM ET
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
Wednesday
August 5, 2026
4:01 PM ET
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update